TrovaGene (NASDAQ:TROV) released its quarterly earnings results on Wednesday. The medical research company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.15, Fidelity Earnings reports. The company had revenue of $0.09 million during the quarter. TrovaGene had a negative return on equity of 188.93% and a negative net margin of 2,970.66%.
Shares of NASDAQ:TROV traded up $0.01 during midday trading on Thursday, reaching $0.78. The company’s stock had a trading volume of 400 shares, compared to its average volume of 2,484,623. The company has a market cap of $13.27 million, a P/E ratio of -0.12 and a beta of 0.14. TrovaGene has a 1 year low of $0.65 and a 1 year high of $8.64.
Several equities analysts have weighed in on TROV shares. Zacks Investment Research raised TrovaGene from a “sell” rating to a “hold” rating in a research report on Saturday, September 29th. Maxim Group reissued a “buy” rating on shares of TrovaGene in a research report on Monday, August 6th. Finally, ValuEngine raised TrovaGene from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $4.75.
Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.
Featured Article: Capital gains and your 401(k) or IRA
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.